

Disclosure of Support to Patient Organisations and Methods used



Organon Norway - Patient Organisations Disclosure

Year of Data: 2025
Publication Date: 9-Oct-2026

Recipient Name	Address	Country	Description of the program / initiative	Type of support	Amount
Hodepine Norge Trøndelag	Jonsvannsveien 558, Jonsvatnet	Norway	Sponsorship of Migraine Event 27-28 Sep 2025	Financial	60 000 NOK
				Total	60 000 NOK

Organon: Methods used for Patient Organisation Disclosure 2025

Country: Norway

Data year: 2025

Year of publication: 2026

This memo describes the methods used to publish financial and non-monetary benefits by Organon to patient organisations in Norway. Patient organizations are non-profit entities that are mainly composed of patients and/or caregivers who represent and support the needs of patients and/or caregivers.

Patient organisations enable the pharmaceutical industry to become more patient-focused and improve their knowledge on the needs of people living with these diseases and conditions.

Activities between pharmaceutical companies and patient organizations are regulated by the European Federation of Pharmaceutical Industries and Associations (EFPIA) and the local regulations of each country, and all cooperation between these parties must be transparent. Organon acts in accordance with these codes to ensure transparency and openness between the pharmaceutical industry and patient organisations across Europe.

This memo serves as a supplemental document to the annual report on the financial benefits to patient organizations. The memo describes the methods used to meet the requirements of EFPIA and local regulation regarding the disclosure.

This report presents:

- The form of support Organon provides to the patient organization, e.g. financial, indirect or non-financial support
- The nature of the support provided, referred to in the section ‘Description of the program / initiative’
- The amount of support provided in the local currency to the extent that the form of support has been economic.

Cross-border activities:

Regardless of which Organon entity provides the support, all Patient organisations whose principal place of business or business address is in Norway are disclosed by Organon Norway.

Report date:

Organon publishes the paid and non-monetary support in the previous calendar year no later than 6 months after the end of the reporting period in question (e.g., support for year 2025 will be published no later than 30 June 2026). The published information will be available for three (3) years on the company website.